Trial Profile
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- 25 Feb 2022 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 13 May 2018 to 13 Dec 2020.
- 04 Sep 2018 Planned primary completion date changed from 13 May 2018 to 14 Dec 2019.